Chairman Zhou Jie resigns just three months after taking on the role.

BeiGene has been cleared to start Chinese trials of its PARP inhibitor BGB-290, one of a portfolio of homegrown drugs that aims to challenge Western dominance…

Chinese development venture will boost biotech R&D space in South San Francisco by a fifth, says city manager.

By selling its Wako chemicals unit, the top Japanese drugmaker Takeda could raise $1 billion for reinvestment in its pipeline.

Eisai said a U.S. FDA nod for a Phase III trial for Alzheimer’s oral candidate BACE inhibitor E2609 will see it continue the joint effort with Biogen.

Mesoblast said its RA candidate MPC-300-IV met safety and toleration goals in a Phase II study for patients who fail to continue to respond to widely used…

Hutchison China MediTech has accelerated and expanded work on c-MET inhibitor candidate savolitinib through an amended license deal with AstraZeneca.

Singapore's Agency for Science, Technology and Research will work with Merck on potential ways to help reach into cells with macrocyclic peptides.